Vectra DA has become an important tool for rheumatologists and patients alike since its’ introduction in November 2010. The information provided by the Vectra DA test has given physicians and patients an objective measure with which to make critical treatment decisions. Crescendo Bioscience has continued to study Vectra DA since its introduction. Each patient’s data has added to the overall body of knowledge and understanding of Vectra DA. The current database contains data from more than 357,000 unique Vectra DA patients. Through the continued research on Vectra DA coupled with feedback from practicing clinicians we have come to understand that age, gender, and adiposity (body fat) may influence a patient’s test score. Moving forward, the Vectra DA score will be adjusted to account for age, gender, and adiposity. The original twelve-protein biomarker algorithm remains the same. This improvement in the score is something that the rheumatology community has asked for and it will give each Vectra DA patient a very individualized score.
We are also adding an additional number to the new report, the MID, or minimally important difference. We define MID as the smallest absolute change likely to reflect a statistically meaningful change. This number is 7.6 in patients with moderate or high disease activity. The MID will help rheumatologists judge what action should be taken when assessing the change in Vectra DA score from one patient visit to the next.
Below you will find a description of the new Vectra DA report with an explanation of each section of the report. We hope you find this enhanced Vectra DA score and new test report to be of greater value.